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ABSTRACT: Engineering robust protein production and
puriﬁcation of correctly folded biotherapeutic proteins in
cell-based systems is often challenging due to the require-
ments for maintaining complex cellular networks for cell
viability and the need to develop associated downstream
processes that reproducibly yield biopharmaceutical pro-
ducts with high product quality. Here, we present an alter-
native Escherichia coli-based open cell-free synthesis (OCFS)
system that is optimized for predictable high-yield protein
synthesis and folding at any scale with straightforward
downstream puriﬁcation processes. We describe how the
linear scalability of OCFS allows rapid process optimization
of parameters affecting extract activation, gene sequence
optimization, and redox folding conditions for disulﬁde
bond formation at microliter scales. Efﬁcient and predict-
able high-level protein production can then be achieved
using batch processes in standard bioreactors. We show how
a fully bioactive protein produced by OCFS from optimized
frozen extract can be puriﬁed directly using a streamlined
puriﬁcation process that yields a biologically active cytokine,
human granulocyte-macrophage colony-stimulating factor,
produced at titers of 700mg/L in 10h. These results repre-
sent a milestone for in vitro protein synthesis, with potential
for the cGMP production of disulﬁde-bonded biotherapeu-
tic proteins.
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Introduction
Cell-free protein synthesis systems have distinct advantages
over traditional in vivo methods for protein production
(Endo and Sawasaki, 2006; Jermutus et al., 1998). The
absence of a requirement to maintain cell viability allows
optimizationof theprotein synthetic capacity of thecell-free
extract to produce a single protein. The absence of a cell
wall allows for addition of non-natural factors to the open
system in order to manipulate transcription, translation,
and folding to provide precise modulation of the protein
expression process (Jewett and Swartz, 2004b). Cell-free
systems derived from Escherichia coli have a long history as
experimental tools for exploring the molecular biology of
transcription and translation (Jewett et al., 2002; Noren
et al., 1989; Spirin et al., 1988; Zubay, 1973) and have been
utilized as a basis for developing in vitro protein production
systems at small scales.
Cell-free protein production at the multigram and
kilogram scale, an essential starting requirement for bio-
therapeutic productionprocesses, has been hampered by the
lack of scalable systems amenable to standard bioreactor
conﬁgurations at large scale. Voloshin and Swartz (2008)
reported production of 385mg/L of soluble protein
corresponding to a 3-disulﬁde bonded protein IGF-1 to
1-L scale. However, the fraction of correctly folded and
functional protein was not reported, and different
yields were reported using different reaction vessel designs.
Consistent and robust performance at a wide range of
scales is important for using a system as a general
production technology and the time and cost of biologic
drug discovery and production process development can be
substantially reduced with systems that scale in a predictable
and efﬁcient manner from high-throughput screening to
manufacturing.
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synthesis for the production of recombinant proteins
requires efﬁcient and reproducible preparation of large
volumes of active cell extracts (Liu et al., 2005), stable
and cost-effective energy generating systems (Jewett and
Swartz, 2004a), and the maintenance of stable pools of
precursor molecules required for high-level protein synth-
esis. For example, the overall protein synthetic capacity of
E. coli extracts has been increased by genetically engineering
pathways responsible for recycling key amino acid precursor
molecules, leading to the development of the E. coli
strain KGK10 (Calhoun and Swartz, 2006; Knapp et al.,
2007; Michel-Reydellet et al., 2004).
Here, we extend the E. coli-based system developed
bySwartz and coworkerstoshowhow scalableopencell-free
synthesis (OCFS) can be optimized for high-level produc-
tion of a multi-disulﬁde-bonded protein, granulocyte-
macrophage colony-stimulating factor (rhGM-CSF),
through detailed analysis and reﬁnement of several process
elements including: extract preparation and storage, opti-
mization of synthetic gene sequences and redox parameters,
process scale-up, and downstream product puriﬁcation
steps.Weshowthatafterfulloptimization,theOCFSsystem
can produce active rhGM-CSF, a four-helix bundle human
cytokine with two disulﬁde bonds required for functional
activity. The system is linearly scalable and can achieve
yields of rhGM-CSF of 700mg/L in 10h over  10
6 range in
volumes to 100L. This linear scalability allows for rapid
analysis of multiple parameters affecting transcription,
protein synthesis, and folding in 24- or 96-well plates for
high-throughput optimization of product and process
parameters. Finally, the absence of a cell-lysis step after
protein production, allows rapid and consistent protein
puriﬁcation optimization.
Materials and Methods
Cell Extract Prepared From Strain KGK10 at 200 L Scale
Cell extracts were prepared using a previously engineered
K-12-derivedE.colistrainKGK10[A19DendADtonADspeA
DtnaA metþ DsdaA DsdaB DgshA Dgor TrxB_HAtag;
(Knapp et al., 2007)]. KGK10 was cultured to mid-log
phase[OD595 45OD, 140g/Lofcellwetweight(CWW)],
using glucose and amino acid fed-batch fermentation at
maximal growth rate of 0.7h
 1, essentially as described by
(Zawada and Swartz, 2005), except that the glucose feed rate
was increased manually to ensure excess glucose was present
at the time of harvest. Fermentations were performed in a
200L Sartorius D200 bioreactor equipped with pH and
temperature control, four bafﬂes, three six-bladed impellers,
sampling tube, air sparger, pO2-probe, and exhaust gas
analysis. Cells were pelleted by centrifugation at >14,000g
for 45min at 48C two times using tubular bowl centrifuges
(Model Z101; Carl Padberg, Schnell Zentrifugenbau GmbH,
Lahr, Germany) or a disc-stack continuous centrifuge
(ModelCSC6withhydrostop;GEAWestfaliaGmbH,Oelde,
Germany) with a maximum bowl speed of 12,000rpm and a
feed ﬂow rate of 2.0–2.5L/min, then resuspended and
repelleted two times with S30 buffer and stored at  808C.
The thawed cell-paste was suspended in 2mL of S30
buffer per g CWW, cells were lysed in a homogenizer
(EmulsiFlex-C55A; Avestin, Manheim, DE) at 20,000psi
and chilled to 0–48C using a heat exchanger on the
homogenizer outlet. Cell debris and insoluble components
were removed by centrifugation at 12,000g for 45min at 48C
two times. A typical 200L fermentation yielded >1.1L
clariﬁed extract/kg CWW with a total protein concentration
of 20–25g/L. For optimization of extract activity (‘‘run-off
reaction’’), clariﬁed extract samples (1mL) were collected
at various pre-incubation times at 25, 30, and 378C,
centrifuged at >15,000g to remove particulates, and then
the supernatant was ﬂash frozen in liquid nitrogen for
subsequent analysis of protein synthesis activity, measured
by rhGM-CSF production as described below. Once optimal
pre-incubation conditions were identiﬁed, the extracts were
activated at large scale and centrifuged at 14,000g for 35min
in tubular bowl centrifuges. The supernatant was frozen in
liquid nitrogen and stored at  808C in polyethylene bags or,
for long-term stability studies, in Freeze-Pak Bio-container
bags (60mL; Charter Medical Ltd, Winston-Salem, NC), or
at  408C in cryostorage vials.
Gene Expression Constructs
Expression of rhGM-CSF (GenBank Accession No.
AAA52578.1) with an N-terminal methionine was
under the control of the T7 promoter using added T7
RNA polymerase (RNAP) for transcription. Genes were
designed using Biomax ProteoExpert (https://ssl.biomax.de/
ProteoExpert/index.jsp) or DNA 2.0 GeneDesigner (https://
www.dna20.com/genedesigner2/) algorithms (Welch et al.
2009) and were synthesized (DNA 2.0, Menlo Park, CA).
Detailed methods for large-scale production of plasmid DNA
and accessory proteins T7 RNAP and E.coli DsbC are
described in Supplementary Methods.
OCFS Protein Synthesis Reaction Conditions
Cell-free extracts were thawed to room temperature
and incubated with 50mM iodoacetamide for 30min, as
previously described (Knapp et al. 2007). OCFS reactions
were run at 308C for up to 10h containing 30% (v/v)
iodoacetamide-treated extract with 8mM magnesium
glutamate, 10mM ammonium glutamate, 130mM potas-
sium glutamate, 35mM sodium pyruvate, 1.2mM AMP,
0.86mM each of GMP, UMP, and CMP, 2mM amino
acids (1mM for tyrosine), 4mM sodium oxalate, 1mM
putrescine, 1.5mM spermidine, 15mM potassium phos-
phate, 100nM T7 RNAP, 2–10mg/mL plasmid DNA
template, 1–10mM E. coli DsbC. Reduced (GSH) and
oxidized (GSSG) glutathione were added to a total
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was calculated using the Nernst equation with E
0¼
 205mV as the standard potential of the GSH/GSSG
couple at 308C and pH 7 (Wunderlich and Glockshuber,
1993).
Proteins produced at 250mL scale or less were monitored
by incorporation of l-[U-
14C]-leucine (300mCi/mmole; GE
Life Sciences, Piscataway, NJ) by measuring the TCA-
precipatible soluble and total protein in 24-well plates or
Petri dishes without shaking (Voloshin and Swartz, 2005),
or in 96-well plates at 30mL scale (with shaking). Proteins
were analyzed by reducing or non-reducing 12% SDS–PAGE
gels with Sypro staining (Invitrogen, Carlsbad, CA) according
to the manufacturer’s recommendations and analyzed by
autoradiography using a Storm 840 PhosphoImager.
At larger scales, concentrations of rhGM-CSF were deter-
mined using reversed phase HPLC (ZORBAX 300SB-C8
5mm, 4.6 250mm; Agilent, Santa Clara, CA) at 408C with
a ﬂow rate of 1.5mL/min in 100mM triethylammonium
acetate, pH 7.0 buffer. rhGM-CSF eluted 4min into a 35–
45.5%, acetonitrile gradient carried out over 7min.
OCFS Reaction Process Scale-up
OCFS reaction conditions were linearly scaled to 0.3L in a
0.5L stirred tank reactor (Biostat Q; B. Braun Biotech Inc.,
Bethlehem,PA),tothe4Lscaleina10Lfermentor(ES10;B.
Braun Biotech Inc.), and to the 100L scale in a 200L
fermentor. Antifoam (1/12,000 v/v of 31R1 Pluronic
1
surfactant; BASF, Florham Park, NJ) was added, the pH
maintained at 7.0 and dissolved oxygen concentration [O2]
 20% by adjusting agitation speed and the [O2] in the
sparge gas at1vvm and aninitial ratio of 90% airto10% O2.
The 4 and 100L scale reactions were pressurized at 5psi to
reduce foaming and 1mg/mL ciproﬂoxacin was added to
inhibit bacterial growth.
Protein Puriﬁcation
A portion of the rhGM-CSF was puriﬁed directly from
the 100L cell-free reaction as follows. Four liters of the 10h
cell-free reaction were diluted to 40L with 10mM sodium
phosphate pH 6.5 and loaded onto 600mL of DEAE
Sepharose FastFlow resin (GE Life Sciences), washed with
10L of 10mM sodium phosphate pH 6.5, followed by
gradient elution with 10mM sodium phosphate, pH 6.5,
0.2M NaCl over 30 column volumes. The DEAE puriﬁed
product pool was concentrated 95-fold by tangential ﬂow
ﬁltration with a 3kD MW cutoff membrane (Pellicon 2
regenerated cellulose; Millipore, Billerica, MA). The con-
centrated product pool was then processed in multiple size
exclusion chromatography runs using Sephacryl S-100
High-Resolution resin (GE Life Sciences) packed into
two 1L columns to give a combined column length of
approximately 1m. The overall recovery was 65%, and
endotoxin and host cell protein levels were within
speciﬁcations (Supplementary Methods). The activity of
rhGM-CSF was assayed by the dose-dependent stimulation
of the proliferation of human TF-1 cells as previously
described (Goerke and Swartz, 2008).
Results
Cell Fermentation and Extract Preparation
The OCFS bioproduction process starts with high-density
cell culture with fast growth rates in order to optimize
the yield of ribosomes that is directly correlated with cell
growth rate (Zawada and Swartz, 2006). We modiﬁed
the short protocol of Liu et al. (2005) for extract production
using fermentation under conditions of excess glucose
at harvest, rather than glucose-limited fermentation.
Several extract process improvements included, introduc-
tion of high-throughput centrifugation using a disc-stack
centrifuge capable of processing hundreds of liters of
cells, increased dilution of the cell suspension prior to
homogenization to improve subsequent lysate clariﬁcation,
as well as removal of the requirement for a dialysis
step following the optimized pre-incubation protocol, as
described below.
Optimized Extract Activation and Storage Stability
An essential step in the preparation of the extract is the pre-
incubation prior to the initiation of T7-based transcription
and translation of protein product, sometimes referred to as
a translation ‘‘run-off’’ procedure or pre-incubation step
(Zubay, 1973).Although the exact nature of the biochemical
steps associated with cell-extract pre-incubation are not
known in detail, we chose to investigate the effect of time
and temperature of the pre-incubation step on the synthesis
activityoftheclariﬁedextractasmeasuredbysolublerhGM-
CSF production at small scale as described in Materials and
Methods section.
Figure 1a shows that clariﬁed extracts pre-incubated at
25, 30, or 378C show differential amounts of rhGM-CSF
are produced in the subsequent 5h cell-free synthesis
reaction. Optimal extract activation was achieved at 308C
using a 2.5-h pre-incubation period and this was conﬁrmed
with extract produced from cells harvested using large
scale disc-stack centrifugation, as shown in Figure 1B. All
subsequentreactions usedextractpre-incubated underthese
activation conditions.
We also investigated the production capacity of
activated extract after freezing and storage at  408C and
 808C for periods up to 1 year (data not shown).
Full rhGM-CSF production activity was retained, even
after multiple freeze–thaw cycles, suggesting that active
extract can be stored frozen for subsequent rapid protein
production.
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Synonymous gene mutations do not alter the encoded
protein, but they can radically inﬂuence gene expression
(Welch et al., 2009). To investigate how, we designed several
gene constructs with synonymous codons designed to alter
(a) the instability of the 5’ mRNA sequence or (b) codon
usage based on the algorithms described by Welch et al.
(2009); see Supplementary Methods. As shown in Figure 2,
synonymous codon variations lead to variable expression
yields. We conclude that either gene sequence optimization
method can give reasonable protein yields if multiple gene
sequences are screened in the cell-free synthesis reaction.
Higher throughput methods based on expression from
linear DNA templates may allow a more rapid and extensive
screening of this important optimization parameter (Son
et al. 2006).
Optimization of Disulﬁde Bond Formation
Conditions of the OCFS reaction can be directly manipu-
lated to provide an optimized environment for both protein
expression and folding. In contrast, the ability of E. coli to
correctly fold recombinant proteins containing multiple
disulﬁde bonds is limited, due the reducing environment of
the cytosol and the limited capacity for co-translational
folding (Baneyx and Mujacic, 2004; Endo and Sawasaki,
2006; Jermutus et al., 1998; Kawasaki et al., 2003; Kolb et al.,
2000; Maier et al., 2005; Yang et al., 2004).
Figure3showsthattheoptimalconditionsforproduction
of soluble, folded rhGM-CSF are controlled both by the
Figure 1. Protein synthesis activity is dependent on the time and temperature of
extract pre-incubation. a: Aliquots of the cell-free extract were incubated at various
times and temperatures (&:3 7 8C, *:3 0 8C, and ~:2 5 8C) to optimize the cell-free
synthesis activity. b: Aliquots of the cell-free extract prepared using a tubular bowl
centrifuge (*) or from cells harvested with large scale disc-stack continuous
centrifugation, followed by lysate clariﬁcation in a tubular bowl centrifuge (*) were
incubatedat308Cforvarious times.TheconcentrationofrhGM-CSF producedafter5h
ina60mLscalereactionfromthesevariouspre-incubationconditionswasdetermined
by [
14C]-leucine incorporation as described in the Materials and Methods section. CVs
were  10% and the protein samples were  95% soluble for all time points.
Figure 2. Yields of soluble rhGM-CSF for several gene sequences designed
using (a) ProteoExpert 50 mRNA optimization or (b) DNA 2.0 codon bias algorithms as
described in the Materials and Methods section. The expression of soluble rhGM-CSF
was measured by [
14C]-leucine incorporation in 250mL. CVs were  10%, for all
constructs tested. The gene sequence of GM-CSF1 (Supplementary Methods) was
used to optimize cell-free expression in scale-up experiments.
Figure 3. Combinatorial optimization of protein folding in the OCFS system.
Response surface of redox potential and DsbC concentration on soluble expression
of rhGM-CSF. The expression of soluble rhGM-CSF was measured by [
14C]-leucine
incorporationina96-wellplateforIAM-treatedextractasafunctionoftheinitialredox
potential of added [GSSG]tot¼5mM and DsbC concentration. For reference, the redox
potential of the E. coli cytosol is  270mV.
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disulﬁde isomerase, DsbC, that catalyzes disulﬁde bond
rearrangement (Yang et al., 2004). These experiments were
carried out in 96-well microtiter scale as measured by the
amount of soluble rhGM-CSF produced. Under optimized
redox conditions the ratio of soluble:total GM-CSF was
 95%, consistent with correctly folded disulﬁde bonds,
subsequently conﬁrmed by MS analysis of rhGM-CSF
produced under these optimized conditions.
Optimization of protein synthesis yield required us
to balance efﬁcient translation, which requires reducing
conditions (Traut and Haeeni, 1967; Yang et al., 2004), with
protein folding of correct disulﬁde bonds that requires a
more oxidizing environment. DsbC must be maintained in a
reduced state to be able to catalyze the rearrangement of
non-native disulﬁde bonds but has a non-speciﬁc folding
chaperone activity as well. The high DsbC concentrations
required for efﬁcient soluble protein yield suggests that the
folding chaperone activity of DsbC dominates, although the
drop-off in soluble yield under more oxidizing conditions is
consistent with a requirement for reduced DsbC for efﬁcient
disulﬁde isomerase activity (Ryabova et al., 1997).
OCFS is Linearly Scalable from Microscale to Large
Scale Reaction
We used the optimization parameters described above to
deﬁne process parameters for scale-up, without changes
in volumetric performance of the system at all scales.
Figure 4 shows that the OCFS process exhibits linear
scalability overa  10
6changein reaction volume for rhGM-
CSF, with yields of 700mg/L after 10h. This high yield of
fully soluble protein makes the requirement for refolding of
rhGM-CSF produced in normal bacterial fermentation
processes (Berges et al., 1996; Libby et al., 1987) unnecessary
and simpliﬁes subsequent downstream processing (vida
infra).
OCFS is Efﬁcient
The overall efﬁciency of the OCFS system compares
favorably with corresponding efﬁciencies for protein
translation in vivo (Table I). Elongation rates of  1 amino
acid (aa) per second per ribosome are about 20-fold higher
than comparable eukaryotic cell-free systems (Endo and
Sawasaki, 2006; Kawasaki et al., 2003), but smaller than the
rate of 10–20aas
 1 in vivo for rapidly growing E coli.
Similarly, initiation rates in vitro are smaller than estimated
Figure 4. The rate of soluble rhGM-CSF production is independent of scale from
plates, to stirred tank reactors, to large-scale bioreactors. The initial slopes corre-
sponds to a translation rate of  1 peptide bond per second per ribosome. The
concentrations of rhGM-CSF weredetermined by [
14C]-leucine incorporation at 250mL
scale, and by RP HPLC analysis at larger scales, as described in the Materials and
Methods section. CVs were  10% and the proteins were  95% soluble for all time
points. Lines are shown for visual purposes only.
Table I. Ribosomal translation in vivo and in vitro
a
Translation system
Translation efﬁciency
Productive
synthesis time (h) References
Initiation
rate
b (s
 1)
Elongation rate
(AAs
 1ribosome
 1)
E. coli cell 0.5 10–20
c 5–24 Gromadski and Rodnina (2004);
Kierzek et al. (2001); Parker (1989)
OCFS system 0.0015
d  1
e  10 This work
Cytomim system 0.017  1  4 Underwood et al. (2005);
Voloshin and Swartz (2008)
PURE system 2 1 Shimizu et al. (2001)
Wheat germ extract (WGE) 0.05
f  2 Kawasaki et al. (2003)
aAt 378C, unless otherwise indicated.
bInitiation rate is the rate of ribosome clearance, as described by Kierzek et al. (2001).
cTranslation rate estimated based on in vivo data for E. coli in minimal or rich medium or estimated from single-turnover experiments.
dDetermined from the kinetics of GFP production using the model of Kierzek et al., unpublished results.
eTranslation rate at 308C derived from initial translation rate: 150mg/L/h (Fig. 4), rhGM-CSF MW¼15kD, and an active ribosome concentra-
tion¼300nM (Supplementary Fig. S5).
fBatch mode scFv synthesis using eukaryotic wheat germ extract (WGE) translation. The elongation rate for a 26kD scFv is estimated from the observed
maximal synthesis rate of 18mg/mL/h total protein, 85% soluble protein, a WGE A260¼42; where 1 A260¼20nM eukaryotic ribosomes. The translation
elongation rate is 10 times slower in eukaryotes.
1574 Biotechnology and Bioengineering, Vol. 108, No. 7, July, 2011rates in vivo. In vivo expression of heterologous proteins
must compete with the protein synthesis required for
cell growth and viability, so that the effective heterologous
protein synthesis rate in vivo may be lower. The slower
translation rate may also aid in efﬁcient co-translational
folding of rhGM-CSF in the presence of the directly added
DsbC chaperone.
The yields achieved here were obtained using standard
stirred tank bioreactors in batch mode without feeding
supplemental reagents over the 10h production process.
OCFS is able to produce protein for longer times compared
to other in vitro protein synthesis systems in a comparable
batch mode (Table I), due to the ability to maintain
steady state levels of NTPs generated by active oxidative
phosphorylation pathways. As alternatives, continuous or
semi-continuous formats of cell-free protein synthesis
that require a supply of high-energy NTP substrates and
a reservoir to remove inhibitory byproducts have been
developed (Endo and Sawasaki, 2006; Jewett and Swartz,
2004b; Spirin et al., 1988). Although continuous-feed
approaches increase the duration of protein synthesis, they
are not scalable, are expensive, and are unwieldy due to
membrane fouling for both high-throughput screening and
large-scale production.
OCFS Allows Efﬁcient Downstream Protein Puriﬁcation
In engineering an effective large-scale production method
for biologic products it is important to design a system that
uses standard downstream process equipment and reduces
the requirement for multiple manipulations of the product
during the puriﬁcation process. We therefore developed
a streamlined two-column process for puriﬁcation of
rhGM-CSF directly from the cell-free production extract,
as outlined in Figure 5.
Because the cell-free reaction product pool contains
soluble, correctly folded protein product and is substantially
reduced in endotoxin levels and other cellular debris,
it could be loaded directly onto an anion exchange resin,
without signiﬁcant degradation in column performance
during multiple puriﬁcation runs. Subsequent concentra-
tion by tangential ﬂow ﬁltration and removal of host cell
proteins by size exclusion chromatograpy (SEC)-yielded
fully bioactive product with 65% overall recovery of high
purity rhGM-CSF.
To assess protein quality produced by the OCFS system,
we used a series of common comparability protocols
in biopharmaceutical manufacturing (Chirino and Mire-
Sluis, 2004), as summarized in Figure 6 and Supplementary
Methods. We conﬁrmed the absolute mass and correct
disulﬁde bonding patterns by LC-MS, and LC-MS/MS
sequencing, SEC was used to determine purity, and
the biological activity of rhGM-CSF was determined in a
cell-based proliferation assay. The purity achieved could
be considered suitable for therapeutic use but could also
be improved further using three-step puriﬁcation. We
conclude that OCFS can readily produce proteins of
pharmaceutical grade quality at commercially relevant
yields and scales.
Discussion
Several cell-based secretion systems produce biologically
active GM-CSF in E. coli (Berges et al., 1996; Libby et al.,
1987), yeast [50–60mg/L; (Price et al., 1987)], Aspergillus
niger [0.64mg/L;(Kim et al. 2000)], Pichia pastoris (200–
250mg/L; (Sainathan et al., 2005) and 130mg/L;
[Bhatacharya et al., 2007)], and insect cells (11–45mg/
L;[Chiou and Wu, 1990)]. In general, substantial losses of
product due to refolding, ﬁltration, and extensive column
chromatography steps are required to isolate homogenously
pure product in these systems. Cell-free protein synthesis of
GM-CSF as well as other small, disulﬁde-bonded proteins
has been described previously at small scale (Goerke and
Swartz, 2008; Kawasaki et al., 2003; Ryabova et al., 1997; Son
et al., 2006; Yang et al., 2004).
Figure 5. Analysis of process puriﬁcation steps used in the production of
pharmaceutical-grade rhGM-CSF. a: Process ﬂow diagram for protein puriﬁcation
(b) Cell-free reaction product pool was visualized, using non-reducing SDS–PAGE, by
14C autoradiography of leucine incorporation at 5h that measures only protein
produced, or by Sypro staining of all proteins in the extract at 10h. Autoradiography
indicatesincorporationof
14C-leucinecorresponding tothemolecularweight ofrhGM-
CSF and conﬁrms that only rhGM-CSF was produced because the T7 RNAP limits
transcription to the T7 promoter on the plasmid added to the reaction, with no
evidence for aberrant protein products produced from native RNAP transcription. c:
Non-reducing SDS–PAGE of the process puriﬁcation pools. Lane 1: Anion exchange
pool. Lane 2: Tangential ﬂow ﬁltration pool. Lane 3: SEC ﬁnal product pool.
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(>95% correctly folded multi-disulﬁde-bonded protein),
high yield (700mg/L protein over 10hr), linearly scalable
( 10
6 fold), and high-recovery (>65%) system for
industrial production of disulﬁde-bonded proteins such
as GM-CSF. Using the open nature of cell-free synthesis we
optimizedseveral factors affecting transcription,translation,
and folding to predictably identify conditions for scalable
production of a disulﬁde-bonded protein to the 100L scale.
In this in vitro synthetic biology-based system, experimental
data built from an understanding of the energy source as
well as transcription, translational, and protein folding
components are sufﬁcient to guide design and testing
of protein expression conditions in a microtiter plate format
with predictable properties at any scale. More complex
secondary effects associated with in vivo gene expression
and regulatory networks are avoided. For example, in T7-
based systems in vivo, transcription, translation, and folding
are uncoupled. The uncoupling mediated by T7 RNAP may
in turn mediate protein aggregation. However, after full
optimization of plasmid, T7 RNAP, and redox conditions,
>95% of the protein produced is soluble, there is no
evidence of signiﬁcant misfolded aggregates formed as
measured by non-reducing SDS–PAGE autoradiography
(Fig. 5b), or detected in the ﬁnal product (Fig. 6c).
Previous optimization strategies for cell-free protein
expression have sampled parameters sparsely and thus
cannot be generalized to the more complex, ﬁnely balanced
networks of protein synthesis and folding described here.
Instead, we found that one must ﬁrst assemble and experi-
mentally characterize interacting networks of myriad system
components at small scale to create generalizable response
surfaces such as those in Figures 1 and 3 with quantitative
predictive capabilities for process scale-up.
The OCFS system uses a K-12-derived production strain
as the basis for a cell-line banked under cGMP conditions.
Multiple protein products can now be produced on an as
needed basis from the same stored frozen extract produced
from this strain. For example, similar scalable results to 4L
have been obtained for a single-chain antibody fragment
Figure 6. rhGM-CSF is correctly folded and functional. a: Liquid chromatography–Mass spectrometry analysis of intact mass of 14604.78Da corresponds to the expected
average neutral mass of 14604.75Da. Two minor product related impurities were observed corresponding to removal of the ﬁrst two amino acids (-M and -MA). These peak
intensities donotcorrespondaccuratelytotherelativeamountofproduct related impurities. b:Basepeakchromatogramof aV8proteasedigestion ofrhGM-CSF. Thetwo peptides
with disulﬁde bridges labeled V7¼9 and V8¼11 (underlined) coincide with the theoretical masses with correct disulﬁde bridge formation. The V7¼9 linkage was conﬁrmed by
tandem MS and the V8¼11 by accurate mass. Other observed V8 digest peptides are marked accordingly. Digest peptides denoted with a plus sign indicate a missed cleavage. c:
Analytical size exclusion chromatogram of puriﬁed rhGM-CSF on a Tosoh TSKgelG3000SWXL column, ﬂow rate 0.5mL/min. d: The effective dose 50, ED50 <0.1ng/ml of rhGM-CSF
induced proliferation of human TF-1 cells, corresponds to a speciﬁc activity of 14 10
6IU/mg, comparable to commercially available E. coli-derived rhGM-CSF protein as a positive
control. [Color ﬁgure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/bit]
1576 Biotechnology and Bioengineering, Vol. 108, No. 7, July, 2011(scFv), anti-IL-23 scFv (1g/L in 10h) and an anti-IL13Ra1
Fab antibody with ﬁve disulﬁde bonds (300mg/L in 9h;
manuscript in preparation). Use of a single cell-line coupled
with the speed of process optimization inherent in the
linearly scalable OCFS protein production system should
allow for decreases in the timelines for biopharmaceutical
protein production and process development.
We have developed the OCFS production process using
standard microbial fermentation and process equipment
knowntoscaletothousandsoflitersundercGMPstandards.
Additional efforts to improve this production process
toward cGMP compliance include (a) developing methods
for sterile ﬁltration of the extract, (b) establishing extract
process production reproducibility, (c) establishing the
translational ﬁdelity of OCFS produced proteins (Heibeck
et al., manuscript in preparation), and (d) accurate cost-
modelingofthereagentsandotherprocessvariables.Finally,
we aim todevelop a molecular understanding of the limiting
factorsaccountingforthetimeandtemperaturedependence
of extract activation shown in Figure 1, by quantitative LC-
MS-based proﬁling of proteins and metabolites (Roy and
Becker,2007),inordertoimproveproteinproductionyields
further.
The OCFS system is limited to producing proteins with
only a few post-translational modiﬁcations such as disulﬁde
bonds and proteolytic processing (Son et al., 2006); other
therapeutic protein classes such as glycosylated proteins
are currently outside the scope of OCFS at large scale.
However, OCFS has the potential for synthesis of proteins
containing site-speciﬁcally incorporated non-natural
amino acids (Noren et al., 1989) without the requirement
for orthogonal tRNA synthetase-tRNA pairs or limitations
to cellular uptake of non-natural amino acids (Antonczak
et al. 2009). This will allow the engineering of novel post-
translationally modiﬁed proteins using the scalable
OCFS system.
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